Abstract: The present application provides the use of an acridinedione compound in the preparation of an antidiabetic medicament, which belongs to the field of biomedical technology. The present application demonstrates for the first time that the acridinedione compound can improve insulin resistance by activating and upregulating GPR40 protein expression, participating in GPR40-PPAR?-PI3K/Akt-GLUT4 signaling pathway, promoting insulin secretion and increasing glucose consumption in liver and muscle tissue. The target of the acridinedione compound is the GPR40 receptor, its insulinotropic effect is glucose-dependent, and its hypoglycemic effect disappears when peripheral blood glucose falls below a certain level. The preparation of the acridinedione compound into an antidiabetic medicaments will provide entirely new options and strategies for the treatment of diabetes.